Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group

Janna A Hol, Marry M van den Heuvel-Eibrink, Norbert Graf, Kathy Pritchard-Jones, Jesper Brok, Harm van Tinteren, Lisa Howell, Arnauld Verschuur, Christophe Bergeron, Leo Kager, Serena Catania, Filippo Spreafico, Annelies M C Mavinkurve-Groothuis

10 Citationer (Scopus)

Abstract

While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

OriginalsprogEngelsk
TidsskriftPediatric Blood and Cancer
Vol/bind65
Udgave nummer2
Sider (fra-til)e26849
ISSN1545-5009
DOI
StatusUdgivet - feb. 2018

Fingeraftryk

Dyk ned i forskningsemnerne om 'Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group'. Sammen danner de et unikt fingeraftryk.

Citationsformater